X
<

Who's Watching TEVA Now?

PART:
1 2 3 4 5 6 7 8 9
Who's Watching TEVA Now? PART 1 OF 9

Teva Pharmaceutical on the Street: Analysts’ Recommendations in September

Recent approvals

In August 2017, the FDA (US Food and Drug Administration) approved Teva Pharmaceutical Industries’ (TEVA) Austedo for the treatment of adult individuals with tardive dyskinesia. In April 2017, the FDA approved Austedo for the treatment of chorea associated with Huntington’s disease patients.

In August 2017, the FDA approved Teva’s Qvar RediHaler inhalation aerosol for the maintenance treatment of asthma as a prophylactic therapy in patients aged four years and over.

Teva Pharmaceutical on the Street: Analysts’ Recommendations in September

Interested in TEVA? Don't miss the next report.

Receive e-mail alerts for new research on TEVA

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Analysts’ recommendations

Of the 26 analysts tracking Teva in September 2017, none have recommended a “strong buy,” while four analysts have recommended a “buy,” and 19 have recommended a “hold.” Three analysts recommended a “sell.”

Around ~15% of the analysts have recommended some form of a “buy” rating for TEVA. On September 10, 2017, the stock had consensus 12-month target price of $25.00, which represents a ~61.3% return on investment.

Notably, the iShares MSCI EAFE Value ETF (EFV) invests ~0.20% of its total portfolio in TEVA. EFV also invests ~2.6% of its total portfolio in Novartis (NVS), which commercializes its generic drugs through its subsidiary, Sandoz.

Peer ratings

Of the 21 analysts tracking Mylan (MYL) in September 2017, four have suggested a “strong buy,” while ten have suggested a “buy.” Seven analysts have suggested a “hold,” while none have recommended any form of a “sell.”

Around 67% of the analysts recommended some form of a “buy” rating. On September 10, 2017, Mylan had a consensus 12-month target price of $40.12, which represents a ~24.98% return on investment.

Of the 22 analysts tracking Pfizer (PFE) in September, only one has recommended a “strong buy,” while ten have recommended a “buy.” Ten recommended a “hold,” but none has recommended any form of a “sell” or “strong sell.” Around 50% of the analysts recommended some form of a “buy” rating.

On September 10, Pfizer had consensus 12-month target price of $37.45, which represents a ~9.8% return on investment.

X

Please select a profession that best describes you: